Hong Kong, November 28, 2025 – Ping An Biomedical Co., Ltd. (Nasdaq: PASW), referred to as “the Company,” confirmed today that it has received a Minimum Bid Price Deficiency Letter from Nasdaq.
The Company was informed by the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) on November 24, 2025, that it no longer satisfies Nasdaq’s continued listing criterion, specifically Nasdaq Listing Rule 5550(a)(2), which mandates a minimum bid price of $1 per share. This determination was made due to the Company’s closing bid price between October 10, 2025, and November 20, 2025.
Nasdaq has granted the Company a compliance period of 180 calendar days, extending until May 25, 2026, to re-establish adherence to Nasdaq’s continued listing standards. If the Company fails to regain compliance within this initial period, it might qualify for a further 180-calendar-day extension, provided it meets the market value requirement for publicly held shares and all other initial listing criteria for The Nasdaq Capital Market, excluding the bid price rule. This extension would also require the Company to submit written notification of its plan to rectify the shortfall during the secondary compliance period, potentially through a reverse stock split. Nevertheless, if it becomes apparent that the Company cannot resolve the deficiency, or if it otherwise does not qualify, Nasdaq will issue a notice indicating that the Company’s securities will be removed from listing.
The Company is presently assessing various strategies to restore compliance and aims to promptly meet Nasdaq’s ongoing listing obligations. While the Company commits to employing all reasonable endeavors to comply with Rule 5550(a)(2), there is no guarantee that it will successfully regain compliance with this specific rule or remain compliant with other Nasdaq continued listing requirements.
ABOUT PING AN BIOMEDICAL CO., LTD.
Ping An Biomedical Co., Ltd. operates as a comprehensive Supply Chain Management (SCM) service provider within the apparel sector. Additionally, the company is an innovative enterprise focused on providing advanced solutions in healthcare and biomedical technology.
FORWARD-LOOKING STATEMENTS
This announcement includes statements that are forward-looking. Such forward-looking statements carry inherent known and unknown risks and uncertainties, stemming from the Company’s current outlook, including aspects like the trading of its Ordinary Shares or the conclusion of the Offering. Investors can identify many, though not all, of these statements through terms like “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may,” or comparable phrases. While the Company considers the expectations conveyed in these forward-looking statements to be reasonable, it cannot guarantee their accuracy. The Company advises investors that actual outcomes could significantly deviate from projected results and urges them to review the risk factors detailed in the Company’s final prospectus and other filings with the SEC before making any investment choices concerning the Company’s securities. The Company disclaims any obligation to publicly update or amend any forward-looking statements to reflect subsequent events, circumstances, or shifts in its expectations, unless legally mandated.
Contacts
Ping An Biomedical Co., Ltd. Investor Relations Contact:
Building 13, No. 1 Headquarters, No. 5 Kechuang 2nd Street, Tongzhou District, Beijing
Telephone: +8618910841158
Email:
